Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer

Trial Profile

Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PEMBRO-RT

Most Recent Events

  • 10 Apr 2021 Results (n=72) assessing immunogenomic mechanisms of response and resistance to combined radiation and immunotherapy in patients with advanced non-small cell lung cancer from PEMBRO-RT trial, presented at the 112th Annual Meeting of the American Association for Cancer Research.
  • 14 Aug 2020 Status changed from active, no longer recruiting to completed.
  • 31 May 2020 Results of pooled analysis validating and exploring whether RT improves mNSCLC patient responses to immunotherapy presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top